Emergency testing for antineutrophil cytoplasmic antibodies combined with a dialog-based policy between clinician and biologist: effectiveness for the diagnosis of ANCA-associated vasculitis

Internal and Emergency Medicine

Volumn 10, Issue 3, 2015, Pages 315-319

  Sayegh, Johnny ^a,b   Poli, Caroline ^a,b   Chevailler, Alain ^a,b   Subra, Jean François ^a,b   Beloncle, François ^a,b   Deguigne, Pierre Antoine ^a,b   Beauvillain, Céline ^a,b   Augusto, Jean François ^a,b  

^a LUNAM Université   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

ANCA; ANCA associated vasculitis; Emergency

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; BLOOD; COOPERATION; EMERGENCY; FEMALE; HUMAN; MALE; MIDDLE AGED; PUBLIC RELATIONS; TIME TO TREATMENT;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; COOPERATIVE BEHAVIOR; EMERGENCIES; FEMALE; HUMANS; INTERPROFESSIONAL RELATIONS; MALE; MIDDLE AGED; TIME-TO-TREATMENT;

EID: 84939939204     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-014-1141-0     Document Type: Article

References (16)

1. Beauvillain C, Delneste Y, Renier G, Jeannin P, Subra JF, Chevailler A (2008) Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them? Clin Rev Allergy Immunol 35(1–2):47–58. doi:10.1007/s12016-007-8071-9
2. Jennette JC, Falk RJ, Hu P, Xiao H (2013) Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 8:139–160. doi:10.1146/annurev-pathol-011811-132453
3. Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, van der Giessen M, van der Hem GK, The TH et al (1989) Association between active Wegener’s granulomatosis and anticytoplasmic antibodies. Arch Intern Med 149(11):2461–2465
4. Subra JF, Michelet C, Laporte J, Carrere F, Reboul P, Cartier F, Saint-Andre JP, Chevailler A (1998) The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? Clin Nephrol 49(1):15–18
5. Tur BS, Suldur N, Ataman S, Tutkak H, Atay MB, Duzgun N (2004) Anti-neutrophil cytoplasmic antibodies in patients with rheumatoid arthritis: clinical, biological, and radiological correlations. Jt Bone Spine: revue du rhumatisme 71(3):198–202. doi:10.1016/j.jbspin.2003.04.002
6. Aslam A, Newman TL, Misbah SA (2003) Audit of the clinical usefulness of a rapid qualitative ELISA screen for antimyeloperoxidase and antiproteinase 3 antibodies in the assessment of patients with suspected vasculitis. J Clin Pathol 56(10):775–777
7. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, Hagen EC, Jayne D, Jennette JC, Paspaliaris B, Pollock W, Pusey C, Savage CO, Silvestrini R, van der Woude F, Wieslander J, Wiik A (1999) International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 111(4):507–513
8. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, McEvoy R, Pusey C, Pollock W, Trevisin M, Wiik A, Wong R, International Group for Consensus Statement on T, Reporting of Antineutrophil Cytoplasmic A (2003) Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 120(3):312–318. doi:10.1309/WAEP-ADW0-K4LP-UHFN
9. Arnold DF, Timms A, Luqmani R, Misbah SA (2010) Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients. J Clin Pathol 63(8):678–680. doi:10.1136/jcp.2009.072504
10. Mandl LA, Solomon DH, Smith EL, Lew RA, Katz JN, Shmerling RH (2002) Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? Arch Intern Med 162(13):1509–1514
11. Sinclair D, Saas M, Stevens JM (2004) The effect of a symptom related “gating policy” on ANCA requests in routine clinical practice. J Clin Pathol 57(2):131–134
12. Robinson PC, Steele RH (2009) Appropriateness of antineutrophil cytoplasmic antibody testing in a tertiary hospital. J Clin Pathol 62(8):743–745. doi:10.1136/jcp.2009.064485
13. Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U (2002) Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 103(2):196–203. doi:10.1006/clim.2001.5200
14. Tsiveriotis K, Tsirogianni A, Pipi E, Soufleros K, Papasteriades C (2011) Antineutrophil cytoplasmic antibodies testing in a large cohort of unselected greek patients. Autoimmun Dis 2011:626495. doi:10.4061/2011/626495
15. Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 13(7):723–729. doi:10.1016/j.autrev.2014.02.007
16. Catanoso M, Pipitone N, Magnani L, Boiardi L, Salvarani C (2011) New indications for biological therapies. Intern Emerg Med 6(Suppl 1):1–9. doi:10.1007/s11739-011-0667-7